If you have been reading about thymosin beta-4 fragment and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Supplied as a lyophilised cake in sealed vials |
| Solubility class | Freely soluble in water | Polar and charged side chains dominate the sequence |
| Typical storage temperature | -20 °C or below | Dry and dark; a desiccant is often recommended |
| Identity confirmation | Mass spectrometry | Observed mass compared with the theoretical value |
| Common synonyms | Thymosin beta-4 fragment | Also written as T beta 4 fragment 17-23 |
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
"The discovery of radium". Lateral Science. UK. 8 July 2012. Archived from the original on 9 March 2016. Retrieved 13 May 2017. Radium water bath in Oklahoma. markwshead.com (photographic images). "Radium, radioactive". NLM Hazardous Substances Databank. U.S. National Institutes of Health. Archived from the original on 1 July 2018. "Annotated bibliography for radium". Alsos Digital Library for Nuclear Issues. Lexington, VA: Washington and Lee University. Archived from the original on 25 June 2019. "Radium". The Periodic Table of Videos. University of Nottingham.
== Side effects == The main side effects of relugolix for uterine fibroids include abnormal uterine bleeding (24.6–48.6% vs. 6.3% for placebo), hot flashes (42.8–45.5% vs. 0% for placebo), heavy menstrual bleeding (12.1–49.3% vs. 9.4% for placebo), headache (12.3–15.2%), and excessive sweating (9.4–15.2% vs. 0% for placebo). In addition, decreased bone mineral density occurs with relugolix (21.7% decrease by week 12, 24.4% decrease by week 24).
In 1027 and 1044, Patriarch Poppo of Aquileia, who rebuilt the cathedral of Aquileia, entered and sacked neighbouring Grado, and, though the Pope reconfirmed the Patriarch of the latter in his dignities, the town never fully recovered, though it continued to be the seat of the Patriarchate until its formal transference to Venice in 1450. In the fourteenth century, the Patriarchal State reached its largest extension, stretching from the Piave river to the Julian Alps and northern Istria. The seat of the Patriarchate of Aquileia had been transferred to Udine in 1238, but returned to Aquileia in 1420 when Venice annexed the territory of Udine. In 1445, the defeated patriarch Ludovico Trevisan acquiesced in the loss of his ancient temporal estate in return for an annual salary of 5,000 ducats allowed him from the Venetian treasury. Henceforth only Venetians were allowed to hold the title of Patriarch of Aquileia. The Patriarchal State was incorporated into the Republic of Venice with the name of Patria del Friuli, ruled by a provveditore generale or a luogotenente living in Udine.
== In vivo vs In vitro == In vivo staining (also called vital staining or intravital staining) is the process of dyeing living tissues. By causing certain cells or structures to take on contrasting colours, their form (morphology) or position within a cell or tissue can be readily seen and studied. The usual purpose is to reveal cytological details that might otherwise not be apparent; however, staining can also reveal where certain chemicals or specific chemical reactions are taking place within cells or tissues. In vitro staining involves colouring cells or structures that have been removed from their biological context. Certain stains are often combined to reveal more details and features than a single stain alone. Combined with specific protocols for fixation and sample preparation, scientists and physicians can use these standard techniques as consistent, repeatable diagnostic tools. A counterstain is stain that makes cells or structures more visible, when not completely visible with the principal stain.
Sources: en.wikipedia.org
=== Transversion === A single case of a homozygous transversion mutation of the gene encoding for leptin was reported in January 2015. It leads to functional leptin deficiency with high leptin levels in circulation. The transversion of (c.298G → T) changed aspartic acid to tyrosine at position 100 (p.D100Y). The mutant leptin could neither bind to nor activate the leptin receptor in vitro, nor in leptin-deficient mice in vivo. It was found in a two-year-old boy with extreme obesity with recurrent ear and pulmonary infections. Treatment with metreleptin led to "rapid change in eating behavior, a reduction in daily energy intake, and substantial weight loss."
In 1900, the German colonial administration of Nauru granted phosphate rights to British businessman John T. Arundel's Pacific Islands Company (PIC). The PIC was replaced by the Pacific Phosphate Company (PPC) in 1902, with German interests holding around one-third of the company's share capital. Production commenced in 1906, largely relying on indentured labour, with Australia and New Zealand as the primary markets. In 1914, following the outbreak of the First World War, the Australian Naval and Military Expeditionary Force occupied Nauru, with an agreement reached whereby the Australian military would assume administrative control of the island and the PPC would continue phosphate operations. Following the end of the war, Nauru was made a League of Nations mandate under the joint trusteeship of Australia, New Zealand and the United Kingdom, with Australia retaining administration of the island. In 1919, the three trustees signed the Nauru Island Agreement, which entitled them to the phosphate of Nauru through the British Phosphate Commissioners. They bought back all the assets of the PPC for more than 3.5 million pounds on 1 July 1920, and started to manage it directly on 1 January 1921, after a six-month transition period of PPC management. Most of PPC's former employees were retained by the BPC.
The antigens are memorised by these cells so that subsequent exposure to the same type of antigens will stimulate a secondary response, in which a higher concentration of antibodies specific for the antigens are reproduced rapidly and efficiently in a short time for the elimination of the pathogen. Under specific circumstances, low doses of vaccines are given initially, followed by additional doses named booster doses. Boosters can effectively maintain the level of memory cells in the human body, hence extending a person's immunity.
== Economic impact == Though the many advances of HPLC and monoliths are highly visible within the confines of the analytical and pharmaceutical industries, it is unlikely that general society is aware of these developments. Currently, consumers may witness technology developments in the analytical sciences industry in the form of a broader array of available pharmaceutical products of higher purity, advanced forensic testing in criminal trials, better environmental monitoring, and faster returns on medical tests. In the future, presumably, this may not be the case. As medicine becomes more individualized over time, consumer awareness that something is improving their quality of care seems more likely. The further thought that monoliths or HPLC are involved is unlikely to concern the general public, however. There are two main cost drivers behind technological change in this industry. Though many different analytical areas use LC, including food and beverage industries, forensics labs, and clinical testing facilities, the largest impetus toward technology developments comes from the research and development and production arms of the pharmaceutical industry. The areas in which high-throughput monolithic column technologies are likely to have the largest economic impact are R&D and downstream processing. From the Research and Development field comes the desire for more resolved, faster separations from smaller sample quantities. The only phase of drug development under direct control of a pharmaceutical company is the R&D stage.
== Uses and Impact == Labour was induced or stimulated after random allocation of the mothers to one of three oxytocics (prostaglandin E2 orally, oxytocin intravenously, or demoxytocin buccally).Using as models, the neurohypophyseal nonapeptide hormone oxytocin and its analogue deaminooxytocin, several directed routes to formation of sulfur-sulfur bridges have been developed and evaluated. PGE2 tablets (Prostin) were given to 109 parturients and demoxytocin resoriblets (Sandopart) to 84. Use of oral oxytocics for stimulation of labor in cases of premature rupture of the membranes at term. A randomized comparative study of prostaglandin E2 tablets and demoxytocin resoriblets. The efficacy of oral PGE2 tablets and buccal demoxytocin (resoriblets) for the induction of labor in cases of premature rupture of the membranes (PROM) after the 37th week of gestation has been evaluated in a prospective, randomized investigation of 193 women.
Sources: en.wikipedia.org
{\displaystyle {\begin{aligned}\varphi :\ &\rho \left({\partial _{t}u_{\varphi }}+u_{r}{\partial _{r}u_{\varphi }}+{\frac {u_{\varphi }}{r\sin \theta }}{\partial _{\varphi }u_{\varphi }}+{\frac {u_{\theta }}{r}}{\partial _{\theta }u_{\varphi }}+{\frac {u_{r}u_{\varphi }+u_{\varphi }u_{\theta }\cot \theta }{r}}\right)\\&\quad =-{\frac {1}{r\sin \theta }}{\partial _{\varphi }p}\\&\qquad +\mu \left({\frac {1}{r^{2}}}\partial _{r}\left(r^{2}{\partial _{r}u_{\varphi }}\right)+{\frac {1}{r^{2}\sin ^{2}\theta }}{\partial _{\varphi }^{2}u_{\varphi }}+{\frac {1}{r^{2}\sin \theta }}\partial _{\theta }\left(\sin \theta {\partial _{\theta }u_{\varphi }}\right)+{\frac {2\sin \theta {\partial _{\varphi }u_{r}}+2\cos \theta {\partial _{\varphi }u_{\theta }}-u_{\varphi }}{r^{2}\sin ^{2}\theta }}\right)\\&\qquad +{\frac {1}{3}}\mu {\frac {1}{r\sin \theta }}\partial _{\varphi }\left({\frac {1}{r^{2}}}\partial _{r}\left(r^{2}u_{r}\right)+{\frac {1}{r\sin \theta }}\partial _{\theta }\left(u_{\theta }\sin \theta \right)+{\frac {1}{r\sin \theta }}{\partial _{\varphi }u_{\varphi }}\right)\\&\qquad +\rho g_{\varphi }\\[8px]\end{aligned}}}
=== India === The Communist Party of India and its affiliates condemned the US strikes in Venezuela. The Indian National Congress denounced the US's unilateral actions in Venezuela, accusing the United States for transgressing the settled principles of international law, the United Nations Charter and numerous international treaties.
The American cockroach (Periplaneta americana) is the largest species of cockroach routinely found in homes, and often considered a pest. In certain regions of the U.S. it is colloquially known as the waterbug, though it is not a true waterbug since it is not aquatic, nor a Hemipteran. It is also known as the ship cockroach, kakerlac, and Bombay canary. It is often misidentified as a palmetto bug. Despite their name, American cockroaches are native to Africa and the Middle East. They are believed to have been introduced to the Americas only from the 17th century onward as a result of human commercial patterns, including the Atlantic slave trade.
== Effect on microorganisms == Low O2 and high CO2 concentrations in packages are effective in limiting the growth of Gram negative bacteria, molds and aerobic microorganisms, such as Pseudomonas spp. High O2 combined with high CO2 could have bacteriostatic and bactericidal effects by suppression of aerobes by high CO2 and anaerobes by high O2. CO2 has the ability to penetrate bacterial membrane and affect intracellular pH. Therefore, lag phase and generation time of spoilage microorganisms are increased resulting in shelf life extension of refrigerated foods. Since the growth of spoilage microorganisms are suppressed by MAP, the ability of the pathogens to grow is potentially increased. Microorganisms that can survive under low oxygen environment such as Campylobacter jejuni, Clostridium botulinum, E. coli, Salmonella, Listeria and Aeromonas hydrophila are of major concern for MA packaged products. Products may appear organoleptically acceptable due to the delayed growth of the spoilage microorganisms but might contain harmful pathogens. This risk can be minimized by use of additional hurdles such as temperature control (maintain temperature below 3 degrees C), lowering water activity (less than 0.92), reducing pH (below 4.5) or addition of preservatives such as nitrite to delay metabolic activity and growth of pathogens.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.
It corresponds to the actin-binding region of thymosin beta-4. Commercial synthesis reproduces that seven-residue stretch, usually with an acetyl group on the N-terminus.
It is not authorised as a medicine in the United States or the European Union and is distributed as a research chemical. Labels consequently carry research-use-only statements rather than clinical indications.
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.